Early Basal Cortisol Level as a Predictor of Hypothalamic-Pituitary-Adrenal (HPA) Axis Function After Pituitary Tumor Surgery.


Journal

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
ISSN: 1439-3646
Titre abrégé: Exp Clin Endocrinol Diabetes
Pays: Germany
ID NLM: 9505926

Informations de publication

Date de publication:
Nov 2020
Historique:
pubmed: 16 5 2019
medline: 13 8 2021
entrez: 16 5 2019
Statut: ppublish

Résumé

The purpose of this study was to evaluate the clinical relevance of the early postoperative basal cortisol level in assessing the postoperative hypothalamic-pituitary-adrenal (HPA) axis function after pituitary tumor surgery. We performed a prospective observational study that enrolled 83 patients operated for pituitary adenoma or other sellar lesions at the University Hospital Center Zagreb between December 2013 and April 2017 (44 nonfunctioning pituitary adenomas, 28 somatotropinomas, 5 craniopharyngiomas, 2 prolactinomas resistant to medical therapy and 4 other lesions - Rathke's cleft cyst, arachnoid cyst, chondroma and gangliocytoma). Exclusion criteria were Cushing's disease, chronic therapy with glucocorticoids prior to surgery and preoperative adrenal insufficiency. Early postoperative basal cortisol levels (measured on the second postoperative day) and the Synacthen stimulation test (performed 3 months after the surgery with the peak cortisol level of>500 nmol/L considered as a normal response) were analyzed to assess HPA axis function during follow-up. ROC analysis showed a cut-off of the basal cortisol level of ≥300 nmol/L measured on the second postoperative day to predict normal postoperative HPA axis function with the sensitivity of 92.31%, specificity of 87.14% and positive predictive value of 57.14%. The basal cortisol level on the second postoperative day is a valuable tool to predict integrity of the HPA axis after pituitary tumor surgery. Our data suggest that the cortisol level of ≥300 nmol/L accurately predicts adrenal sufficiency and that in these patients glucocorticoid therapy can be withdrawn.

Identifiants

pubmed: 31091548
doi: 10.1055/a-0885-1568
doi:

Substances chimiques

Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

709-714

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Tanja Skoric Polovina (TS)

Department of Endocrinology, University Hospital Center Zagreb, Coatia.

Ivana Kraljevic (I)

Department of Endocrinology, University Hospital Center Zagreb, Coatia.

Mirsala Solak (M)

Department of Endocrinology, University Hospital Center Zagreb, Coatia.

Annemarie Balasko (A)

Department of Endocrinology, University Hospital Center Zagreb, Coatia.

Arta Haxhiu (A)

Department of Endocrinology, University Hospital Center Zagreb, Coatia.

Arita Haxhiu (A)

Department of Endocrinology, University Hospital Center Zagreb, Coatia.

Tina Dusek (T)

Department of Endocrinology, University Hospital Center Zagreb, Coatia.
School of Medicine University of Zagreb, Coatia.

Tamara Poljicanin (T)

Croatian Institute of Public Health, Zagreb, Croatia.

Darko Kastelan (D)

Department of Endocrinology, University Hospital Center Zagreb, Coatia.
School of Medicine University of Zagreb, Coatia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH